ClinicalTrials.gov
public full text
Public Domain
Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)
The primary objectives of the trial is to examine the toxicities and efficacies of afatinib and pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)#1101789
- Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)#387154
- S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer#849755
- Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone#842773
- Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck#841819
Record · ID 850320
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive